Fust Matthew K's Form 4 filing
Crinetics Pharmaceuticals, Inc. (CRNX) · filed Mar 22, 2024
- Accession no.
- 0001209191-24-005060
- Filed
- Mar 22, 2024
- Trade date
- Mar 20, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 8 non-derivative transactions and 4 derivative transactions. Open-market sales total $2.65M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Fust Matthew KCIK 0001397266 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 20, 2024 | Common Stock | MOption exerciseAcquired | +12,500 | $23.24 | +$290,500 | 31,036 | Direct | |
| Mar 20, 2024 | Common Stock | SSaleDisposed | −12,500 | $43.57F2 | −$544,625 | 18,536 | Direct | |
| Mar 20, 2024 | Common Stock | MOption exerciseAcquired | +12,500 | $23.23 | +$290,375 | 31,036 | Direct | |
| Mar 20, 2024 | Common Stock | SSaleDisposed | −12,500 | $43.57F2 | −$544,625 | 18,536 | Direct | |
| Mar 20, 2024 | Common Stock | MOption exerciseAcquired | +17,500 | $20.23 | +$354,025 | 36,036 | Direct | |
| Mar 20, 2024 | Common Stock | SSaleDisposed | −17,500 | $43.58F3 | −$762,650 | 18,536 | Direct | |
| Mar 20, 2024 | Common Stock | MOption exerciseAcquired | +17,500 | $18.29 | +$320,075 | 36,036 | Direct | |
| Mar 20, 2024 | Common Stock | SSaleDisposed | −17,500 | $45.50 | −$796,250 | 18,536 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 20, 2024 | Common Stock | MOption exerciseAcquired | +12,500 | $0.00 | $0 | 0 | Direct | |
| Mar 20, 2024 | Common Stock | MOption exerciseAcquired | +12,500 | $0.00 | $0 | 0 | Direct | |
| Mar 20, 2024 | Common Stock | MOption exerciseAcquired | +17,500 | $0.00 | $0 | 0 | Direct | |
| Mar 20, 2024 | Common Stock | MOption exerciseAcquired | +17,500 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $43.57 per share. The range of sales prices on the transaction date was $42.70 to $44.23 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.
Referenced by the price of 2 transactions in Table I.
- F3
The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $43.58 per share. The range of sales prices on the transaction date was $42.70 to $44.23 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.
Referenced by the price of 1 transaction in Table I.